Advisor Resource Council Purchases New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Advisor Resource Council acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,441 shares of the biopharmaceutical company’s stock, valued at approximately $372,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. raised its stake in Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. Cedar Wealth Management LLC grew its position in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the 2nd quarter worth $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 6.8 %

GILD stock opened at $97.90 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.32. The firm has a market capitalization of $121.88 billion, a PE ratio of 119.39, a PEG ratio of 3.13 and a beta of 0.17. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The stock has a 50-day simple moving average of $84.58 and a two-hundred day simple moving average of $74.67.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the business earned $2.29 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,437 shares of company stock worth $5,374,825. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday. Barclays increased their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Truist Financial raised their target price on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Eleven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $90.05.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.